Chapter 11

New Trends in the Design of Drugs Against Alzheimer's Disease


Abstract

<p>First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem.</p> <p>AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors, based on the cholinergic hypothesis (1976).</p> <p>During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic.</p> <p>In this review, we present an overview of the several strategies and new classes of compounds against AD.</p>

Total Pages: 249-284 (36)

Purchase Chapter  Book Details

RELATED BOOKS

.Botanicals and Natural Bioactives: Prevention and Treatment of Diseases.
.Frontiers In Medicinal Chemistry.
.Alkaloids and Other Nitrogen-Containing Derivatives.
.Potential Health Benefits of Biologically Active Peptides Derived from Underutilized Grains: Recent Advances in their Isolation, Identification, Bioactivity and Molecular Analysis.